- Previous Close
156.05 - Open
158.07 - Bid --
- Ask --
- Day's Range
154.43 - 158.90 - 52 Week Range
117.05 - 315.00 - Volume
332 - Avg. Volume
6,508 - Market Cap (intraday)
1.706B - Beta (5Y Monthly) 0.53
- PE Ratio (TTM)
74.42 - EPS (TTM)
2.08 - Earnings Date Feb 11, 2025 - Feb 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Arvee Laboratories (India) Ltd. manufactures and sells various specialized chemicals in India and internationally. The company offers polymer modifiers, including dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate; and contrast media intermediates, such as 5-nitroisophthalic acid, dimethyl 5-nitroisophthalate, monomethyl 5-nitroisophthalate, 5-hydroxyisophthalic acid, 5-aminoisophthalic acid, and dimethyl 5-aminoisophthalate, as well as 3,5-dinitrobenzoic acid and 3,5-diamino benzoic acid. It also provides drug intermediates comprising 2-acetyl thiophene, thiophene-2-carboxaldehyde, 4amino pyridine, and 2chloro5nitrobenzoic acid. In addition, the company exports its products. Arvee Laboratories (India) Ltd. was incorporated in 2012 and is based in Ahmedabad, India.
arveelabs.com65
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: ARVEE.NS
View MorePerformance Overview: ARVEE.NS
Trailing total returns as of 1/15/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARVEE.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARVEE.NS
View MoreValuation Measures
Market Cap
1.72B
Enterprise Value
1.65B
Trailing P/E
75.39
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.63
Price/Book (mrq)
5.54
Enterprise Value/Revenue
4.46
Enterprise Value/EBITDA
33.21
Financial Highlights
Profitability and Income Statement
Profit Margin
4.52%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
333.51M
Net Income Avi to Common (ttm)
15.06M
Diluted EPS (ttm)
2.08
Balance Sheet and Cash Flow
Total Cash (mrq)
75.4M
Total Debt/Equity (mrq)
3.44%
Levered Free Cash Flow (ttm)
--